Is It Rejection – or Something Else?
-
By
-
Jessica Allerton
-
November 17, 2026
-
6 min
Clinical Scorecard: Is It Rejection – or Something Else?
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: Is It Rejection – or Something Else? |
| Key Mechanisms | Mechanisms or clinical associations described in the source article. |
| Target Population | Kidney transplant recipients evaluated for graft dysfunction or injury |
| Care Setting | Care setting described in the source article. |
Key Highlights
- Biopsy and histology remain central to evaluating graft dysfunction, but biopsy samples only a small part of the organ and findings may be difficult to interpret consistently.
- Creatinine and estimated glomerular filtration rate indicate kidney function but do not identify the cause of a change.
- Molecular testing can add information about biological activity in sampled tissue, but does not always establish the cause of injury.
- Rejection, infection, medication toxicity, reduced blood flow, obstruction, and recurrence of the original disease can cause graft dysfunction and may require different management.
- Blood- and urine-based biomarkers are being investigated for monitoring and risk assessment; the source does not support their use as universal replacements for biopsy.
Guideline-Based Recommendations
Diagnosis
- Interpret molecular findings alongside histology, laboratory results, and the patient’s clinical history.
- Donor-specific antibodies suggest an immune response associated with increased risk, but their presence alone does not confirm active rejection.
- A rise in creatinine indicates a change in kidney function but does not reveal its cause.
Management
- Consider the complete diagnostic picture before changing immunosuppressive therapy.
- Use molecular results as complementary information rather than as a standalone determination of every cause of graft dysfunction.
- Assess whether molecular testing changes clinical decisions and improves patient outcomes; diagnostic accuracy and clinical benefit are separate questions.
Monitoring & Follow-up
- Use creatinine and estimated glomerular filtration rate to monitor kidney function and tacrolimus levels to indicate exposure to that medication.
- The source does not establish a role for tracking molecular measurements over time to guide treatment or medication dosing.
- Blood- and urine-based biomarkers are being investigated for monitoring and risk assessment; whether they can guide further evaluation or biopsy decisions requires study.
Risks
- Increasing or changing immunosuppression for presumed rejection could impair control of an infection if infection is driving the injury.
- Immunosuppressive therapies carry risks including infection, certain cancers, and drug toxicity; risks vary with medication, dose, and treatment duration.
- Biopsy sampling limitations and variable interpretation can affect assessment; molecular tests do not eliminate these limitations.
Patient & Prescribing Data
Kidney transplant recipients evaluated for graft dysfunction, rejection, or other forms of injury.
Treatment depends on the cause of graft dysfunction. Rejection is often managed by increasing or changing immunosuppression, while infection, medication toxicity, and other causes may require different management. Decisions should integrate molecular results with histology, laboratory findings, and clinical condition.
Clinical Best Practices
- Use biopsy, laboratory findings, molecular results, and clinical history together when assessing graft injury.
- Recognize that creatinine, estimated glomerular filtration rate, tacrolimus levels, and donor-specific antibodies address different clinical questions.
- For molecular test development, use well-characterized samples, clearly defined diagnoses, relevant clinical information, and reference cohorts reflecting the intended population and setting.
- Assess test performance with independent samples and, ideally, prospective studies.
- Do not assume that a molecular pattern or test result alone provides a definitive diagnosis.
Related Resources & Content
Based on findings from:
Is It Rejection – or Something Else?
Jessica Allerton. The Pathologist, 2026.
https://www.thepathologist.com/issues/2026/articles/november/is-it-rejection-or-something-else/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.